HHBT Financial Statements From 2010 to 2025
| HHBT Stock | USD 0.0001 0.00 0.00% |
Check HH Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HH Biotechnology's main balance sheet or income statement drivers, such as , as well as many indicators such as . HHBT financial statements analysis is a perfect complement when working with HH Biotechnology Valuation or Volatility modules.
HHBT |
HH Biotechnology Holdings Company Profit Margin Analysis
HH Biotechnology's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current HH Biotechnology Profit Margin | 0.36 % |
Most of HH Biotechnology's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, HH Biotechnology Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, HH Biotechnology Holdings has a Profit Margin of 0.3619%. This is 96.56% lower than that of the Real Estate Management & Development sector and 76.03% lower than that of the Real Estate industry. The profit margin for all United States stocks is 128.5% lower than that of the firm.
HH Biotechnology Holdings Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining HH Biotechnology's current stock value. Our valuation model uses many indicators to compare HH Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across HH Biotechnology competition to find correlations between indicators driving HH Biotechnology's intrinsic value. More Info.HH Biotechnology Holdings is rated # 2 in return on equity category among its peers. It is rated # 3 in return on asset category among its peers reporting about 0.53 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for HH Biotechnology Holdings is roughly 1.88 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the HH Biotechnology's earnings, one of the primary drivers of an investment's value.About HH Biotechnology Financial Statements
HH Biotechnology shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although HH Biotechnology investors may analyze each financial statement separately, they are all interrelated. The changes in HH Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses on on HH Biotechnology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
HH Biotechnology Holdings Company engages in health and green industries. HH Biotechnology Holdings Company was incorporated in 1987 and is headquartered in Shenyang, the Peoples Republic of China. HH BIOTECHNOLOGY operates under Real Estate Services classification in the United States and is traded on OTC Exchange. It employs 121 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for HHBT Pink Sheet Analysis
When running HH Biotechnology's price analysis, check to measure HH Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HH Biotechnology is operating at the current time. Most of HH Biotechnology's value examination focuses on studying past and present price action to predict the probability of HH Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HH Biotechnology's price. Additionally, you may evaluate how the addition of HH Biotechnology to your portfolios can decrease your overall portfolio volatility.